RBBP7_HUMAN - dbPTM
RBBP7_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID RBBP7_HUMAN
UniProt AC Q16576
Protein Name Histone-binding protein RBBP7
Gene Name RBBP7
Organism Homo sapiens (Human).
Sequence Length 425
Subcellular Localization Nucleus.
Protein Description Core histone-binding subunit that may target chromatin remodeling factors, histone acetyltransferases and histone deacetylases to their histone substrates in a manner that is regulated by nucleosomal DNA. Component of several complexes which regulate chromatin metabolism. These include the type B histone acetyltransferase (HAT) complex, which is required for chromatin assembly following DNA replication; the core histone deacetylase (HDAC) complex, which promotes histone deacetylation and consequent transcriptional repression; the nucleosome remodeling and histone deacetylase complex (the NuRD complex), which promotes transcriptional repression by histone deacetylation and nucleosome remodeling; and the PRC2/EED-EZH2 complex, which promotes repression of homeotic genes during development; and the NURF (nucleosome remodeling factor) complex..
Protein Sequence MASKEMFEDTVEERVINEEYKIWKKNTPFLYDLVMTHALQWPSLTVQWLPEVTKPEGKDYALHWLVLGTHTSDEQNHLVVARVHIPNDDAQFDASHCDSDKGEFGGFGSVTGKIECEIKINHEGEVNRARYMPQNPHIIATKTPSSDVLVFDYTKHPAKPDPSGECNPDLRLRGHQKEGYGLSWNSNLSGHLLSASDDHTVCLWDINAGPKEGKIVDAKAIFTGHSAVVEDVAWHLLHESLFGSVADDQKLMIWDTRSNTTSKPSHLVDAHTAEVNCLSFNPYSEFILATGSADKTVALWDLRNLKLKLHTFESHKDEIFQVHWSPHNETILASSGTDRRLNVWDLSKIGEEQSAEDAEDGPPELLFIHGGHTAKISDFSWNPNEPWVICSVSEDNIMQIWQMAENIYNDEESDVTTSELEGQGS
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure
ASA (%) Reference Orthologous
Protein Cluster
2 (in isoform 2)Acetylation-29.3420068231
2Acetylation------MASKEMFED
------CCCHHHHHH
29.3422814378
3Phosphorylation-----MASKEMFEDT
-----CCCHHHHHHH
28.0529255136
4Sumoylation----MASKEMFEDTV
----CCCHHHHHHHH
43.59-
42-Hydroxyisobutyrylation----MASKEMFEDTV
----CCCHHHHHHHH
43.59-
4Sumoylation----MASKEMFEDTV
----CCCHHHHHHHH
43.5928112733
4Acetylation----MASKEMFEDTV
----CCCHHHHHHHH
43.5919608861
4Ubiquitination----MASKEMFEDTV
----CCCHHHHHHHH
43.5919608861
6Sulfoxidation--MASKEMFEDTVEE
--CCCHHHHHHHHHH
5.2521406390
10PhosphorylationSKEMFEDTVEERVIN
CHHHHHHHHHHHHHC
23.7121712546
13 (in isoform 2)Phosphorylation-48.1630108239
14MethylationFEDTVEERVINEEYK
HHHHHHHHHHCHHHH
22.55115490439
20PhosphorylationERVINEEYKIWKKNT
HHHHCHHHHHHHCCC
11.1225106551
21SumoylationRVINEEYKIWKKNTP
HHHCHHHHHHHCCCH
45.42-
21AcetylationRVINEEYKIWKKNTP
HHHCHHHHHHHCCCH
45.4222636321
21UbiquitinationRVINEEYKIWKKNTP
HHHCHHHHHHHCCCH
45.4221890473
21SumoylationRVINEEYKIWKKNTP
HHHCHHHHHHHCCCH
45.42-
24UbiquitinationNEEYKIWKKNTPFLY
CHHHHHHHCCCHHHH
39.3521890473
25UbiquitinationEEYKIWKKNTPFLYD
HHHHHHHCCCHHHHH
51.57-
27PhosphorylationYKIWKKNTPFLYDLV
HHHHHCCCHHHHHHH
25.0530177828
31PhosphorylationKKNTPFLYDLVMTHA
HCCCHHHHHHHHHHH
13.9630177828
36PhosphorylationFLYDLVMTHALQWPS
HHHHHHHHHHHHCCC
9.1230177828
60PhosphorylationTKPEGKDYALHWLVL
CCCCCCCEEEEEEEE
17.9728152594
65UbiquitinationKDYALHWLVLGTHTS
CCEEEEEEEEECCCC
1.2621890473
68UbiquitinationALHWLVLGTHTSDEQ
EEEEEEEECCCCCCC
14.1521890473
95PhosphorylationDDAQFDASHCDSDKG
CCCCCCHHHCCCCCC
26.8823401153
99PhosphorylationFDASHCDSDKGEFGG
CCHHHCCCCCCCCCC
46.7629255136
101UbiquitinationASHCDSDKGEFGGFG
HHHCCCCCCCCCCCC
65.38-
1012-HydroxyisobutyrylationASHCDSDKGEFGGFG
HHHCCCCCCCCCCCC
65.38-
101AcetylationASHCDSDKGEFGGFG
HHHCCCCCCCCCCCC
65.3823749302
109PhosphorylationGEFGGFGSVTGKIEC
CCCCCCCEECEEEEE
17.7824732914
111PhosphorylationFGGFGSVTGKIECEI
CCCCCEECEEEEEEE
34.1624732914
113SumoylationGFGSVTGKIECEIKI
CCCEECEEEEEEEEE
26.43-
113AcetylationGFGSVTGKIECEIKI
CCCEECEEEEEEEEE
26.4326051181
113UbiquitinationGFGSVTGKIECEIKI
CCCEECEEEEEEEEE
26.43-
119SumoylationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.37-
119AcetylationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.3716916647
1192-HydroxyisobutyrylationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.37-
119SumoylationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.37-
119UbiquitinationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.37-
119MalonylationGKIECEIKINHEGEV
EEEEEEEEECCCCCC
18.3726320211
130MethylationEGEVNRARYMPQNPH
CCCCCCEEECCCCCC
25.66115490431
142UbiquitinationNPHIIATKTPSSDVL
CCCEEEECCCCCCEE
49.7921890473
143PhosphorylationPHIIATKTPSSDVLV
CCEEEECCCCCCEEE
24.8530266825
145PhosphorylationIIATKTPSSDVLVFD
EEEECCCCCCEEEEE
44.3930266825
146PhosphorylationIATKTPSSDVLVFDY
EEECCCCCCEEEEEC
32.7030266825
153PhosphorylationSDVLVFDYTKHPAKP
CCEEEEECCCCCCCC
13.2628152594
154PhosphorylationDVLVFDYTKHPAKPD
CEEEEECCCCCCCCC
25.4028152594
155AcetylationVLVFDYTKHPAKPDP
EEEEECCCCCCCCCC
41.1725953088
155SumoylationVLVFDYTKHPAKPDP
EEEEECCCCCCCCCC
41.1728112733
155UbiquitinationVLVFDYTKHPAKPDP
EEEEECCCCCCCCCC
41.17-
159MethylationDYTKHPAKPDPSGEC
ECCCCCCCCCCCCCC
55.1723644510
159SumoylationDYTKHPAKPDPSGEC
ECCCCCCCCCCCCCC
55.17-
159AcetylationDYTKHPAKPDPSGEC
ECCCCCCCCCCCCCC
55.1723749302
159UbiquitinationDYTKHPAKPDPSGEC
ECCCCCCCCCCCCCC
55.17-
159SumoylationDYTKHPAKPDPSGEC
ECCCCCCCCCCCCCC
55.1728112733
177UbiquitinationLRLRGHQKEGYGLSW
CCCCCCCCCCCCCCC
47.64-
186UbiquitinationGYGLSWNSNLSGHLL
CCCCCCCCCCCCEEE
32.6521890473
214AcetylationNAGPKEGKIVDAKAI
CCCCCCCCEEECEEE
40.4226051181
214UbiquitinationNAGPKEGKIVDAKAI
CCCCCCCCEEECEEE
40.42-
219UbiquitinationEGKIVDAKAIFTGHS
CCCEEECEEEEECCC
37.24-
257MethylationKLMIWDTRSNTTSKP
CEEEEECCCCCCCCC
25.99-
263UbiquitinationTRSNTTSKPSHLVDA
CCCCCCCCCHHEEEC
48.74-
263AcetylationTRSNTTSKPSHLVDA
CCCCCCCCCHHEEEC
48.7426051181
296PhosphorylationATGSADKTVALWDLR
ECCCCCCEEEEEEHH
16.1421712546
303MethylationTVALWDLRNLKLKLH
EEEEEEHHCCEEEEE
43.92-
306SumoylationLWDLRNLKLKLHTFE
EEEHHCCEEEEEEEC
47.31-
3082-HydroxyisobutyrylationDLRNLKLKLHTFESH
EHHCCEEEEEEECHH
36.31-
308UbiquitinationDLRNLKLKLHTFESH
EHHCCEEEEEEECHH
36.31-
314PhosphorylationLKLHTFESHKDEIFQ
EEEEEECHHCCCEEE
31.48-
316UbiquitinationLHTFESHKDEIFQVH
EEEECHHCCCEEEEE
67.3521906983
325PhosphorylationEIFQVHWSPHNETIL
CEEEEEECCCCCEEE
11.0326714015
340MethylationASSGTDRRLNVWDLS
CCCCCCCCCEEEEHH
33.16-
347PhosphorylationRLNVWDLSKIGEEQS
CCEEEEHHHHCCCCC
21.5421815630
348UbiquitinationLNVWDLSKIGEEQSA
CEEEEHHHHCCCCCH
63.132190698
354PhosphorylationSKIGEEQSAEDAEDG
HHHCCCCCHHHCCCC
36.5830266825
360UbiquitinationQSAEDAEDGPPELLF
CCHHHCCCCCCEEEE
76.3021890473
373PhosphorylationLFIHGGHTAKISDFS
EEEECCCEEEECCCC
32.6823403867
377PhosphorylationGGHTAKISDFSWNPN
CCCEEEECCCCCCCC
31.7120068231
380PhosphorylationTAKISDFSWNPNEPW
EEEECCCCCCCCCCE
30.8220068231
391PhosphorylationNEPWVICSVSEDNIM
CCCEEEEEECHHHHH
19.9720068231
393PhosphorylationPWVICSVSEDNIMQI
CEEEEEECHHHHHHH
23.9620068231
408PhosphorylationWQMAENIYNDEESDV
HHHHHHHCCCCCCCC
28.3020068231
413PhosphorylationNIYNDEESDVTTSEL
HHCCCCCCCCCHHHH
35.0220068231
416PhosphorylationNDEESDVTTSELEGQ
CCCCCCCCHHHHCCC
29.6020068231
417PhosphorylationDEESDVTTSELEGQG
CCCCCCCHHHHCCCC
21.7620068231
418PhosphorylationEESDVTTSELEGQGS
CCCCCCHHHHCCCCC
30.7120068231
425PhosphorylationSELEGQGS-------
HHHCCCCC-------
29.2120068231

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)
Modified Location Modified Residue Modification Type of Upstream Proteins Gene Name of Upstream Proteins UniProt AC of Upstream Proteins Sources
314SPhosphorylationKinaseAMPKA1Q13131
PSP

Functions of PTM Sites
Modified Location Modified Residue Modification Function Reference

Oops, there are no descriptions of PTM sites of RBBP7_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10)
Residue Change SAP Related Disease Reference

Oops, there are no SNP-PTM records of RBBP7_HUMAN !!

Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions
BRCA1_HUMANBRCA1physical
11394910
P66B_HUMANGATAD2Bphysical
11756549
BRCA1_HUMANBRCA1physical
10220405
SIN3A_HUMANSIN3Aphysical
9651585
SAP30_HUMANSAP30physical
9651585
BAF_HUMANBANF1physical
19759913
P66A_HUMANGATAD2Aphysical
16738318
P66B_HUMANGATAD2Bphysical
16738318
BC11B_HUMANBCL11Bphysical
16091750
H31T_HUMANHIST3H3physical
20953179
HAT1_HUMANHAT1physical
20953179
CHD4_HUMANCHD4physical
9790534
SALL2_HUMANSALL2physical
21228219
H31T_HUMANHIST3H3physical
15601853
WAP53_HUMANWRAP53physical
22939629
RBBP4_HUMANRBBP4physical
22863883
NACC2_HUMANNACC2physical
22926524
FA60A_HUMANFAM60Aphysical
26186194
NPAT_HUMANNPATphysical
26186194
SAP30_HUMANSAP30physical
26186194
ING2_HUMANING2physical
26186194
HDAC1_HUMANHDAC1physical
26186194
HDAC2_HUMANHDAC2physical
26186194
KDM5A_HUMANKDM5Aphysical
26186194
ARI4A_HUMANARID4Aphysical
26186194
SIN3A_HUMANSIN3Aphysical
26186194
SIN3B_HUMANSIN3Bphysical
26186194
Z512B_HUMANZNF512Bphysical
26186194
P66A_HUMANGATAD2Aphysical
26186194
SP130_HUMANSAP130physical
26186194
SHPRH_HUMANSHPRHphysical
26186194
PHF12_HUMANPHF12physical
26186194
ARI4B_HUMANARID4Bphysical
26186194
ZN521_HUMANZNF521physical
26186194
ZN423_HUMANZNF423physical
26186194
MBD2_HUMANMBD2physical
26186194
MBD3_HUMANMBD3physical
26186194
CHD3_HUMANCHD3physical
26186194
CHD4_HUMANCHD4physical
26186194
CHD5_HUMANCHD5physical
26186194
MTA2_HUMANMTA2physical
26186194
MTA3_HUMANMTA3physical
26186194
RBBP4_HUMANRBBP4physical
26186194
SUZ12_HUMANSUZ12physical
26186194
BRM1L_HUMANBRMS1Lphysical
26186194
SMCA5_HUMANSMARCA5physical
26186194
SMCA1_HUMANSMARCA1physical
26186194
GATD1_HUMANGATAD1physical
26186194
SP30L_HUMANSAP30Lphysical
26186194
EZH2_HUMANEZH2physical
26186194
BPTF_HUMANBPTFphysical
26186194
LIN9_HUMANLIN9physical
26186194
EED_HUMANEEDphysical
26186194
CDKA1_HUMANCDK2AP1physical
26186194
ING1_HUMANING1physical
26186194
SDS3_HUMANSUDS3physical
26186194
BC11A_HUMANBCL11Aphysical
26186194
FOXK2_HUMANFOXK2physical
26186194
FOXK1_HUMANFOXK1physical
26186194
CCD71_HUMANCCDC71physical
26186194
CCDC8_HUMANCCDC8physical
26186194
BAP18_HUMANC17orf49physical
26186194
BRMS1_HUMANBRMS1physical
26186194
SALL1_HUMANSALL1physical
26186194
ZBTB2_HUMANZBTB2physical
26186194
MTF2_HUMANMTF2physical
26186194
BAHC1_HUMANBAHCC1physical
26186194
CA122_HUMANC1orf122physical
26186194
GNL3_HUMANGNL3physical
26344197
HAT1_HUMANHAT1physical
26344197
HDAC1_HUMANHDAC1physical
26344197
HDAC2_HUMANHDAC2physical
26344197
RBBP4_HUMANRBBP4physical
26344197
DDB1_HUMANDDB1physical
25795299
HDAC1_HUMANHDAC1physical
25885317
SUZ12_HUMANSUZ12physical
28514442
PHF12_HUMANPHF12physical
28514442
MTF2_HUMANMTF2physical
28514442
ZN521_HUMANZNF521physical
28514442
Z512B_HUMANZNF512Bphysical
28514442
CHD5_HUMANCHD5physical
28514442
KDM5A_HUMANKDM5Aphysical
28514442
MTA3_HUMANMTA3physical
28514442
ZN423_HUMANZNF423physical
28514442
BPTF_HUMANBPTFphysical
28514442
BRM1L_HUMANBRMS1Lphysical
28514442
NPAT_HUMANNPATphysical
28514442
P66A_HUMANGATAD2Aphysical
28514442
SP30L_HUMANSAP30Lphysical
28514442
MBD3_HUMANMBD3physical
28514442
MBD2_HUMANMBD2physical
28514442
ARI4B_HUMANARID4Bphysical
28514442
SIN3B_HUMANSIN3Bphysical
28514442
SDS3_HUMANSUDS3physical
28514442
HDAC1_HUMANHDAC1physical
28514442
SHPRH_HUMANSHPRHphysical
28514442
EZH2_HUMANEZH2physical
28514442
SP130_HUMANSAP130physical
28514442
EED_HUMANEEDphysical
28514442
SIN3A_HUMANSIN3Aphysical
28514442
ARI4A_HUMANARID4Aphysical
28514442
SMCA1_HUMANSMARCA1physical
28514442
CHD4_HUMANCHD4physical
28514442
SAP30_HUMANSAP30physical
28514442
ZBTB2_HUMANZBTB2physical
28514442
CDKA1_HUMANCDK2AP1physical
28514442
LIN9_HUMANLIN9physical
28514442
CHD3_HUMANCHD3physical
28514442
BC11A_HUMANBCL11Aphysical
28514442
ING1_HUMANING1physical
28514442
BAHC1_HUMANBAHCC1physical
28514442
SMCA5_HUMANSMARCA5physical
28514442
FOXK2_HUMANFOXK2physical
28514442
CA122_HUMANC1orf122physical
28514442
MTA2_HUMANMTA2physical
28514442
FOXK1_HUMANFOXK1physical
28514442
GATD1_HUMANGATAD1physical
28514442
RBBP4_HUMANRBBP4physical
28514442
SALL1_HUMANSALL1physical
28514442
HDAC2_HUMANHDAC2physical
28514442
ASF1A_HUMANASF1Aphysical
28514442
CCD71_HUMANCCDC71physical
28514442
CCDC8_HUMANCCDC8physical
28514442
DNMT1_HUMANDNMT1physical
28143904
HAT1_HUMANHAT1physical
28143904
ZN827_HUMANZNF827physical
25150861

Drug and Disease Associations
Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.
Regulatory Network of RBBP7_HUMAN

loading...

Related Literatures of Post-Translational Modification
Acetylation
ReferencePubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.
"Quantitative analysis of global ubiquitination in HeLa cells by massspectrometry.";
Meierhofer D., Wang X., Huang L., Kaiser P.;
J. Proteome Res. 7:4566-4576(2008).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, UBIQUITINATION [LARGESCALE ANALYSIS] AT LYS-4, AND MASS SPECTROMETRY.
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis.";
Wang B., Malik R., Nigg E.A., Korner R.;
Anal. Chem. 80:9526-9533(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3; SER-413 AND THR-416,ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions.";
Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.;
Science 325:834-840(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-4 AND LYS-21, AND MASSSPECTROMETRY.
"Substrate and functional diversity of lysine acetylation revealed bya proteomics survey.";
Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T.,Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.-J., Zhao Y.;
Mol. Cell 23:607-618(2006).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-119, AND MASS SPECTROMETRY.
Phosphorylation
ReferencePubMed
"A quantitative atlas of mitotic phosphorylation.";
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.;
Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354, AND MASSSPECTROMETRY.
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle.";
Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.;
Mol. Cell 31:438-448(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-354, AND MASSSPECTROMETRY.
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis.";
Wang B., Malik R., Nigg E.A., Korner R.;
Anal. Chem. 80:9526-9533(2008).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3; SER-413 AND THR-416,ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.
"Global proteomic profiling of phosphopeptides using electron transferdissociation tandem mass spectrometry.";
Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.;
Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007).
Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-413 AND THR-416, ANDMASS SPECTROMETRY.
Ubiquitylation
ReferencePubMed
"Quantitative analysis of global ubiquitination in HeLa cells by massspectrometry.";
Meierhofer D., Wang X., Huang L., Kaiser P.;
J. Proteome Res. 7:4566-4576(2008).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, UBIQUITINATION [LARGESCALE ANALYSIS] AT LYS-4, AND MASS SPECTROMETRY.

TOP